Journal
BEHAVIOURAL PHARMACOLOGY
Volume 22, Issue 3, Pages 275-280Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FBP.0b013e328345f758
Keywords
anxiety; locomotion; 3, 4-methylenedioxymethamphetamine; novelty-based paradigms; psychedelic hallucinogenic drugs; zebrafish
Funding
- Tulane University
- Zebrafish Neuroscience Research Consortium
- NIDA SOAR
- Louisiana Board of Regents
Ask authors/readers for more resources
3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is a potent psychedelic drug inducing euphoria and hypersociability in humans, as well as hyperactivity and anxiety in rodents. Adult zebrafish (Danio rerio) have become a widely used species in neurobehavioral research. Here, we explore the effects of a wide range (0.25-120 mg/l) of acute MDMA doses on zebrafish behavior in the novel tank test. Although MDMA was inactive at lower doses (0.25-10 mg/l), higher doses reduced bottom swimming and immobility (40-120 mg/l) and impaired intrasession habituation (10-120 mg/l). MDMA also elevated brain c-fos expression, collectively confirming the usage of zebrafish models for screening of hallucinogenic compounds. Behavioural Pharmacology 22: 275-280 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available